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Prolonged exposure of human epidermis to excess en-
dogenous or exogenous glucocorticoids can result in
well-recognized cutaneous abnormalities. Here, we de-
termined whether short-term glucocorticoid treatment
would also display adverse e¡ects, speci¢cally on two
key epidermal functions, permeability barrier homeos-
tasis and stratum corneum integrity and cohesion, and
the basis for such changes. In humans 3 d of treatment
with a potent, commonly employed topical glucocorti-
coid (clobetasol), applied topically, produced a dete-
rioration in barrier homeostasis, characterized by
delayed barrier recovery and abnormal stratum cor-
neum integrity (rate of barrier disruption with tape
strippings) and stratum corneum cohesion (lg protein
removed per stripping). Short-term systemic and topi-
cal glucocorticoid produced similar functional defects
in mice, where the basis for these abnormalities was ex-
plored further. Both the production and secretion of la-
mellar bodies were profoundly decreased in topical
glucocorticoid-treated mice resulting in decreased ex-
tracellular lamellar bilayers. These structural changes,
in turn, were attributable to a profound global inhibi-
tion of lipid synthesis, demonstrated both in epidermis
and in cultured human keratinocytes. The basis for the
abnormality in stratum corneum integrity and cohe-
sion was a diminution in the density of corneodesmo-
somes in the lower stratum corneum. We next
performed topical replacement studies to determine
whether lipid de¢ciency accounts for the glucocorti-
coid-induced functional abnormalities. The abnormal-
ities in both permeability barrier homeostasis and
stratum corneum integrity were corrected by topical
applications of an equimolar distribution of free fatty
acids, cholesterol, and ceramides, indicating that gluco-
corticoid-induced inhibition of epidermal lipid synth-
esis accounts for the derangements in both cutaneous
barrier function and stratum corneum integrity/cohe-
sion. These studies indicate that even short-term expo-
sure to potent glucocorticosteroids can exert profound
negative e¡ects on cutaneous structure and function. Fi-
nally, topical replenishment with epidermal physiologic
lipids could represent a potential method to reduce the
adverse cutaneous e¡ects of both topical glucocorticoid
treatment and Cushing’s syndrome. Key words: corneo-
desmosomes/glucocorticoids/lamellar bodies/lipid synthesis/
permeability barrier function/stratum corneum integrity/trans-
epidermal water loss. J Invest Dermatol 120:456 ^464, 2003
C
ushing’s syndrome and prolonged topical or sys-
temic treatment with glucocorticosteroids (GC)
produce a variety of well-recognized cutaneous ab-
normalities including easy bruisibility, cutaneous
atrophy, increased skin fragility, and increased risk
of infection.These atrophogenic cutaneous e¡ects of GC are gen-
erally attributed to negative e¡ects on protein and glucose meta-
bolism. A major function of the skin is the formation of a
permeability barrier between the external milieu and the organ-
ism, and recent studies have shown that chronic GC also nega-
tively impacts epidermal barrier function. In recent studies, we
have found that even short-term increases in endogenous GC in-
duced by psychologic stress and single supraphysiologic doses of
systemic GC appear to impair permeability barrier homeostasis
(Denda et al, 2000; Garg et al, 2001).
The stratum corneum (SC), the outermost layer of the epider-
mis, accounts for the permeability barrier. The SC is a distinctive
two-compartment system, consisting of corneocytes that provide
mechanical resistance embedded in a lipid-enriched extracellular
matrix, which is responsible for the permeability barrier that is
required for terrestrial life. Corneocytes are formed by the term-
inal di¡erentiation of keratinocytes, a process that includes the
cross-linking of proteins such as loricrin and involucrin by trans-
glutaminase to form the corni¢ed envelope, as well as the loss of
DNA and internal organelles. Corneodesmosomes link adjacent
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corneocytes, contributing to the skin’s resistance to injury, which
can be assessed as SC integrity and cohesion based upon resis-
tance to sequential tape stripping and amount of protein removed
per stripping, respectively. The extracellular matrix lipids are or-
ganized into lamellar membranes enriched in free fatty acids,
cholesterol, and ceramides (Downing, 1992; Elias and Feingold,
1999), which are derived from the secretion of lamellar body con-
tents. Lamellar body secretion, in turn, is maintained and replen-
ished by a highly active lipid synthetic apparatus in the
underlying epidermis (Feingold, 1991; Menon et al, 1992). The
importance of the synthetic response is shown by the obser-
vation that inhibition of cholesterol, fatty acid, or ceramide
synthesis prevents the formation of new lamellar bodies and de-
lays barrier recovery (Feingold et al, 1990; Holleran et al, 1991;
Mao-Qiang et al, 1993). Thus, modulations in epidermal lipid
synthesis play a crucial role in the maintenance of permeability
barrier homeostasis.
The aim of this study was to characterize the short-term e¡ects
of systemic and topical GC administration on two key epidermal
functions, permeability barrier homeostasis and SC integrity/co-
hesion. Our results show that these key functions are negatively
impacted in humans by short-term topical GC administration,
and further studies in mice show that GC directly a¡ect the epi-
dermis and the e¡ects are in large part attributable to a profound
inhibition of epidermal lipid synthesis by GC.
MATERIALS AND METHODS
Human studies Three normal male subjects (ages 31^59 y) and four
normal female subjects (ages 20^50 y) without any history of skin
disorders volunteered for this double-blind study, which was approved by
the UCSF Committee for Human Research. Each subject signed a written
informed consent prior to the start of the study. Subjects than applied
clobetasol (0.05%) in a propylene glycol:ethanol (7 : 3 vol/vol) vehicle to a
2.5 cm2 area on one volar forearm and vehicle alone to the contralateral
forearm once per day for 3 d. Transepidermal water loss (TEWL) was
measured at baseline and at 3 and 24 h following barrier disruption by
tape stripping using a Tewameter TM 210 (Courage & Khazaka, Cologne,
Germany). SC integrity was determined by measurement of TEWL after
each sequential stripping with D-Squame tape.
Animal model Male hairless mice (Skh1/Hr), 8^12 wk of age, were
purchased from Charles River Laboratories (Wilmington, MA). All
animal experiments described were conducted in accord with accepted
standards of humane animal care and approved by the local animal
research committee. Clobetasol and dexamethasone were purchased from
Sigma Chemical (St. Louis, MO). 22 mm D-Squame 100 tapes (CuDerm,
Dallas,TX) were used for barrier disruption and collecting SC samples for
protein assay. A Bradford protein assay kit was purchased from Bio-Rad
(Hercules, CA). 14C acetate was purchased from American Radiolabeled
Chemicals (St. Louis, MO).
Animal procedures Clobetasol, 50 ml in propylene glycol:ethanol (7:3
vol/vol) (0.0125%^0.05%), was applied twice daily for 1 or 3 d to one
£ank of hairless mice; the opposing £ank was left untreated or treated
with vehicle alone. Control littermates were treated with vehicle alone on
one £ank. Systemic GC was administered by injecting each mouse
intraperitoneally with 8 mg dexamethasone (450 mg per kg) in propylene
glycol:ethanol (7 : 3 vol/vol) vehicle or vehicle alone once a day for 3 d.
TEWL was measured as parts per million per cm2 per h with an
electrolytic water analyzer (Meeco, Warrington, PA), as described
previously (Grubauer et al, 1989; Menon et al, 1992). Barrier recovery was
determined by measuring TEWL immediately after and 3, 6, and 24 h
after barrier disruption by tape stripping or acetone treatment,
as described previously (Grubauer et al, 1989; Feingold et al, 1990; Holleran
et al, 1991; Mao-Qiang et al, 1993). SC integrity was determined by
measurement of TEWL after each sequential stripping with D-Squame
tape, as described previously (Fluhr et al, 2001).
Two protocols were used to determine the e¡ect of topical lipids on
barrier recovery. First, animals were treated topically twice per day for 3 d
with GC as described above. Immediately after barrier disruption by tape
stripping, a mixture of palmitic acid, cholesterol, and ceramides was
applied in a 1 : 1 : 1 mole ratio in a propylene glycol:ethanol (7 : 3 vol/vol)
vehicle, as described previously (Mao-Qiang et al, 1995; Man et al, 1996).
Control sites were treated with vehicle alone. Barrier recovery was
determined as described above. In the second protocol, animals were
treated topically twice per day for 3 d with GC. Immediately after each
treatment, the animals received a single topical application of the same
lipid mixture, or the vehicle alone, as above. Barrier recovery rates and
SC integrity/cohesion were then compared in lipid- versus vehicle-treated
animals, as above.
Protein assay D-Squame tape was applied to mouse skin with ¢rm
pressure, removed with forceps, and stored in glass scintillation vials. SC
cohesion was quantitated as the amount of protein removed per tape
stripping as previously described (Fluhr et al, 2001).
E¡ects of GC on lipid synthesis in vivo and in vitro Skin samples
were obtained after 3 d of topical treatment or 1 d of systemic treatment
with GC and compared to identically vehicle-treated controls. The
samples were incubated for 2 h at 371C in a solution containing 10 mM
ethylenediamine tetraacetic acid in Dulbecco’s phosphate-bu¡ered saline,
calcium and magnesium free, containing 40 mCi 14C acetate. After
incubation the epidermis was separated from the dermis and the
incorporation of 14C acetate into cholesterol, fatty acids, and ceramides
was determined in the epidermis after saponi¢cation, extraction, and thin
layer chromatography, as described previously (Monger et al, 1988; Feingold
et al, 1990; Holleran et al, 1991; Mao-Qiang et al, 1993).
Second-passage normal human keratinocytes from foreskin were grown
in KGM obtained from Clonetics (Walkersville, MD) with 0.03 mM Ca2þ
to 90%^95% con£uence, subsequently switched to KGM containing 1.2
mM Ca2þ for 3 d, and changed to KGM with 1.2 mM Ca2þ but
without growth factors for 2 d. Finally, normal human keratinocytes were
changed to KGMþ1.2 mM Ca2þ without growth factors, with or
without added dexamethasone (Sigma) 0.01 mM, for 24 h. Subsequently,
14C acetate (50^60 mCi per mmol) (American Radiolabeled Chemicals)
and 1 mM cold acetate (to insure that acetate concentrations do not limit
lipid synthesis) were added to a ¢nal concentration of 8 mCi per ml, and
incubations were carried out for 2 h at 351C. The cells were collected,
saponi¢ed, extracted, and fractioned by thin layer chromatography.
Figure1. Topical GC perturb permeability barrier homeostasis and
decrease SC integrity in humans. Clobetasol 0.05% or vehicle was ap-
plied twice daily for 3 d to the volar forearm. Barrier recovery was mea-
sured following tape stripping (A). SC integrity was measured as described
in Materials and Methods (B). Results are expressed as mean7SEM. n¼ 7 in
both groups.
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Individual lipid bands were scraped from the plates, incubated in Scintisafe
30% (Fisher Scienti¢c, Santa Clara, CA), and counted in a Beckman LS
1800 scintillation counter (Beckman, Fullerton, CA) as described
previously (Monger et al, 1988; Feingold et al, 1990; Holleran et al, 1991;
Mao-Qiang et al, 1993).
Electron microscopy Skin biopsies were taken after the completion of
3 d of topical GC therapy both in the basal state and 3 h after acute barrier
disruption by tape stripping. Samples were processed for electron
microscopy using both 0.5% ruthenium tetroxide and 2% aqueous
osmium tetroxide post¢xation, as described previously (Menon et al, 1992).
Statistical analysis Statistical analyses were performed using paired and
unpaired Student’s t tests. Normal distributions were tested before calculating
the signi¢cance with the t test.When more than two groups were compared,
a further ANOVA was performed, and for po0.05 a post hoc, pairwise
comparison was also calculated using the Bonferroni test. All analyses were
carried out using Prism 3 (GraphPad Software, San Diego, CA).
RESULTS
Topical GC alter SC function in humans We ¢rst
determined if short-term administration of a potent topical GC,
clobetasol, under commonly employed conditions (i.e., 0.05%
twice daily) exerts adverse e¡ects on SC function in humans.
Although topical GC produced neither visible cutaneous
changes nor changes in basal TEWL, a signi¢cant delay in the
kinetics of barrier recovery was evident by 3 d (Fig 1A). The
ability to resist injury and to protect the underlying viable
epidermis from external insults is a crucial function of the SC.
As seen in Fig 1(B), topical GC also produced a signi¢cant
reduction in SC integrity in human skin. Thus, topical GC can
rapidly produce adverse e¡ects on epidermal permeability
barrier function and SC integrity in human skin.
Topical GC treatment impairs murine permeability barrier
homeostasis To assess the basis for GC-induced abnormalities
in human skin, we examined whether topical treatment with
clobetasol would exhibit similar adverse e¡ects in murine
epidermis, which would then allow further mechanistic studies
in this animal model. As in human skin, treatment with topical
GC for 3 d did not perturb basal TEWL. Although 1 d of topical
clobetasol treatment did not signi¢cantly a¡ect barrier recovery
(data not shown), twice daily topical treatment with clobetasol
for 3 d resulted in a delay in barrier recovery after acute barrier
disruption by tape stripping, which was signi¢cant at 3, 6, and 24
h following barrier disruption (Fig 2A^C). The topical-GC-
induced delay in barrier recovery was dose dependent, with
0.05% clobetasol causing a 70% delay in barrier recovery at 3 h,
whereas lower doses (0.0125%) still signi¢cantly delayed barrier
repair but by only about 25% (Fig 2D).
Finally, to determine if the adverse e¡ects of GC on barrier
recovery are speci¢c for tape stripping, we next assessed the
e¡ects of topical GC in an unrelated model of acute barrier
disruption, i.e., recovery after organic solvent treatment.
Animals were treated topically twice per day for 3 d with
clobetasol 0.05%, and then barrier function was disrupted with
acetone treatment. As shown in Fig 2(E), prior topical GC
treatment also delayed barrier recovery in this model of barrier
disruption. Thus, the adverse e¡ects of short-term topical GC on
barrier recovery occur following two unrelated methods of acute
barrier perturbation.
At clobetasol concentrations greater than 0.0125%, barrier
recovery was delayed not only on the clobetasol-treated £ank
but also on the contralateral, vehicle-treated £ank (Fig 2A, B),
indicating that su⁄cient absorption can occur to produce
systemic e¡ects at distal sites as well. Indeed, as reported
previously (Denda et al, 2000), short-term systemic adminis-
tration of GC also delayed permeability barrier recovery (Fig
2F). Yet, as the lower concentration of clobetasol (0.0125%)
inhibited barrier recovery only locally (i.e., barrier recovery was
normal at distal sites, Fig 2C), topical GC can in£uence SC
function locally. Together, these results demonstrate that short-
term topical GC produces negative, local e¡ects on epidermal
barrier function.
Figure 2. Topical GC perturb permeability barrier homeostasis after disruption by tape stripping and acetone. Clobetasol 0.05% (A, E), 0.025%
(B), or 0.0125% (C), or vehicle (contralateral £ank and separate animal) was applied twice daily for 3 d to the £anks of hairless mice followed by tape
stripping (A, B, C, D) or acetone treatment (clobetasol 0.05%, E). Barrier recovery was determined at 3, 6, and 24 h. The dose^response of barrier recovery
at 3 h is shown in panel D. The 100% value is from the control animals treated with vehicle alone. Hairless mice were treated with dexamethasone 8 mg or
vehicle intraperitoneally for 3 d. Barrier recovery determined 6 h following disruption by tape stripping (F). Results are expressed as mean7SEM. n¼ 4
(A, B, C, D, F); n¼15 (E). npo0.05, nnpo0.005, #po0.01, ##po0.0001; ns, not statistically signi¢cant.
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Topical GC treatment impairs integrity and cohesion in
murine SC We next assessed the e¡ects of topical GC on the
integrity of murine SC, de¢ned as the rate of increase in TEWL
with sequential tape stripping, and on SC cohesion, de¢ned as
the amount of protein removed by each sequential tape
stripping. As shown in Fig 3, 3 d of topical clobetasol markedly
reduced the ability of the SC to withstand sequential tape
stripping. Both the incremental increase in TEWL, produced by
sequential tape stripping (integrity) (Fig 3A), and the amount
of protein removed per stripping (cohesion) increased in the
clobetasol-treated £ank (Fig 3B). The clobetasol-induced
reduction in SC integrity was dose dependent, with the higher
dose (0.05%) producing a greater loss of integrity. Yet, in
comparison to permeability barrier homeostasis, higher
concentrations of GC were required to perturb SC integrity
(Fig 2D versus Fig 3C). But, in contrast to barrier recovery, and
regardless of dose, the decrease in SC integrity induced by topical
GC treatment occurred only on the treated £ank, i.e., the
contralateral, vehicle-treated £ank displayed normal integrity
even at the highest clobetasol concentrations. Finally, as observed
with barrier recovery, the deleterious e¡ects on integrity and
cohesion were again not observed after only 1 d of treatment.
Thus, in addition to compromising permeability barrier
homeostasis, short-term topical GC also decrease SC integrity
and cohesion.
The GC-induced delay in barrier recovery is attributable to
decreased lamellar body generation Because experimentally
induced abnormalities in barrier homeostasis are often due to
defects in lamellar body secretion (Feingold et al, 1990; Holleran
et al, 1991; Mao-Qiang et al, 1993; 1995), we ¢rst examined
whether the GC-induced barrier abnormality was associated
with an abnormality in the epidermal lamellar body secretory
system. In mice treated with topical GC for 3 d, as above, there
was a marked reduction in the density (i.e., marker of organelles
per unit volume) of lamellar bodies in the cytosol of the
outermost stratum granulosum (SG) cells (Fig 4A, arrowheads,
versus Fig 4B, open arrows). The decrease in cytosolic lamellar
bodies was associated with a decrease in the quantities of
secreted lamellar body contents at the SG^SC interface (Fig 4A,
open arrows, versus Fig 4B, solid arrows). Moreover, the numbers
(density) of lamellar bodies in SG cells, which responded with a
profound increase following acute barrier disruption, in vehicle-
treated controls was suppressed in GC-treated animals (Fig 5B, C).
These results indicate that short-term GC treatment not only
decreases basal lamellar body production and secretion, but also
inhibits the increase that normally occurs after acute barrier
disruption. Finally, the delay in barrier recovery 3 h following
barrier disruption in the GC-treated mice correlated with a
Figure 3. GC decreases SC integrity and cohesion. Clobetasol 0.05%,
0.025%, or 0.0125% was applied twice daily for 3 d to the £anks of hairless
mice. The contralateral £anks were treated with vehicle alone as were a se-
parate group of control animals (vehicle animals). A group of untreated
control animals was also included. SC integrity (A) and cohesion (B) were
measured as described in Materials and Methods. A dose^response of topical
clobetasol on integrity assessed byTEWL after four D-Squame tape strip-
pings is shown in panel C. Results are expressed as mean7SEM. n¼13
clobetasol, n¼13 vehicle-treated £ank, n¼ 6 vehicle-treated animal, and
n¼ 6 no treatment animals.
Figure 4. Topical GC decrease lamellar body production and secre-
tion in the basal state. Hairless mice were treated topically twice per day
for 3 d with 0.05% clobetasol or vehicle. (A) Electron micrograph of the
SG^SC junction in the epidermis of clobetasol-treated mice shows a thin
layer of lamellar material (open arrows) and fewer lamellar bodies in the cy-
tosol of SG cells (solid arrowheads). (B) The SG^SC junction in the epider-
mis of vehicle-treated mice demonstrates normal bilayer formation (solid
arrows) and abundant lamellar bodies (short open arrows). Magni¢cation bars:
0.50 mm.
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marked reduction in newly secreted lamellar body contents at the
SG^SC interface in comparison to the amount of secreted
contents in vehicle-treated control animals (Fig 5A versus Fig
5D). Together, these results could account for the impairment in
permeability barrier homeostasis in GC-treated animals.
The GC-induced decrease in lamellar body generation
can be attributed to inhibition of epidermal lipid
synthesis Lamellar body formation requires cholesterol, free
fatty acid, and ceramide production, which derive chie£y from
local synthesis within the epidermis (Feingold et al, 1990;
Holleran et al, 1991; Mao-Qiang et al, 1993). Therefore, we next
examined whether the decrease in lamellar body production
with short-term topical GC is, in turn, attributable to inhibition
of epidermal cholesterol, fatty acid, and ceramide synthesis. As
shown in Fig 6(A), short-term topical GC inhibited epidermal
cholesterol, fatty acid, and ceramide synthesis by more than
50%. Additionally, the inhibition of lipid synthesis, induced by
topical GC treatment, is even more apparent following acute
barrier disruption, where GC suppressed lipid synthesis even
more (i.e., by about 80% in comparison to vehicle-treated
samples) (Fig 6B). Lastly, systemic GC administration (see
protocol as above) also profoundly inhibited epidermal
cholesterol and fatty acid synthesis, and to an extent that was
comparable to short-term topical GC treatment (Fig 6C).
Finally, to ascertain whether the e¡ects on epidermal lipid
synthesis can be attributed to a direct e¡ect on keratinocytes, we
next tested the e¡ects of dexamethasone directly on lipid
synthesis in cultured normal human keratinocytes, grown
under high Ca2þ (di¡erentiating conditions). A signi¢cant
decrease in the synthesis of both free fatty acids and cholesterol
occurred in dexamethasone- versus vehicle-treated normal
human keratinocytes (Fig 6D). Together, these results show
that the inhibition of lipid synthesis at the level of the
keratinocytes accounts for the decreased generation of lamellar
bodies and permeability barrier abnormality in GC-treated
epidermis.
The GC-induced abnormalities in SC integrity and cohesion
are associated with reduced corneodesmosome density In
prior studies we have shown that perturbations in SC integrity/
cohesion are associated with reductions in the density of
corneodesmosomes in the lower SC (Fluhr et al, 2001). In
previous studies an increase in SC pH resulted in a decrease in
the number of SC corneodesmosomes (Fluhr et al, 2001). GC
treatment did not alter SC pH, however (data not shown). We
next determined corneodesmosome density in the lower two SC
layers in animals treated for 3 d with topical clobetasol (0.05%) or
vehicle alone. The density of corneodesmosomes was assessed in
coded, randomized micrographs by an unbiased observer. The
quantitative studies showed a signi¢cant decrease (E35%) in the
density of corneodesmosomes in the membrane domains of the
lower SC (vehicle, 6.370.39; clobetasol, 4.370.25 desmosomes
per micrograph; po0.001; n¼10) (Fig 7). These studies show
that the GC-induced alterations in integrity/cohesion can be
attributed to a reduction in SC corneodesmosomes.
Topical lipid replacement reverses GC-induced abnormali-
ties in permeability barrier homeostasis and SC integrity/
cohesion As a further test of the hypothesis that reduced
epidermal lipid synthesis is the cause of the GC-induced
impairment in permeability barrier homeostasis, we next
determined whether exogenous physiologic lipids would reverse
the GC-induced barrier abnormalities. As cholesterol, fatty acids,
and ceramide synthesis are equivalently reduced by GC treatment
(see above), we employed an equimolar mixture of these three
key lipids. Prior studies have shown that such equimolar
mixtures of these physiologic lipids neither accelerate nor inhibit
barrier recovery kinetics in vehicle-treated murine skin (Mao-
Qiang et al, 1995; Man et al, 1996). Yet, a single topical application
of an equimolar lipid mixture of free fatty acids, cholesterol, and
ceramides, applied immediately following acute barrier
disruption by tape stripping, markedly accelerated barrier
recovery in GC-treated animals (Fig 8D), showing further
evidence that a de¢ciency in epidermal lipids accounts in large
part for the barrier abnormality in GC-treated animals. As a
single application of lipids applied immediately following
barrier disruption did not completely restore barrier recovery to
normal, we next determined whether physiologic lipids, applied
twice daily for 3 d immediately after clobetasol treatment, would
further normalize the kinetics of barrier recovery. As shown in
Fig 8(A), coapplications of the equimolar lipid mixture of free
fatty acids, cholesterol, and ceramides totally normalized barrier
recovery kinetics in GC-treated animals. In fact, barrier recovery
actually accelerated slightly in clobetasol- and lipid-cotreated
animals.
We next examined whether coapplications of the eqimolar
physiologic lipid mixture would also improve the GC-induced
abnormalities in SC integrity and cohesion. As shown in
Fig 8(B), (C), both SC integrity and cohesion improved in
clobetasol- and lipid-cotreated animals. Whereas SC inte-
grity almost normalized, however, SC cohesion improved
signi¢cantly but did not normalize under these conditions.
Together, these experiments demonstrate that provision of
Figure 5. Topical GC impairs lamellar body formation and secre-
tion following barrier disruption. Hairless mice were treated topically
twice per day for 3 d with 0.05% clobetasol or vehicle and then the barrier
was disrupted by tape stripping. (A, B) Electron micrograph of the SG^SC
junction of clobetasol-treated mouse epidermis 3 h after acute barrier dis-
ruption by tape stripping. The quantity of secreted lamellar material con-
tinues to be thin (A, B, open arrows), and the expected increased lamellar
body production in response to disruption does not occur (A, arrowhead).
There was also evidence of abnormal lamellar secretion and extracellular
processing (B, white arrowheads). Entombed lamellar bodies (B, white arrow-
heads) indicate incomplete secretion. (D) SG^SC junction of vehicle-treated
mouse epidermis 3 h after acute barrier disruption. Note the mature bi-
layers (arrowheads) and abundant lamellar secretion (solid arrows). Magni¢ca-
tion bars: 0.50 mm.
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exogenous physiologic lipids to GC-treated animals not only
normalizes permeability barrier homeostasis but also improves
the defects in SC integrity and cohesion.
DISCUSSION
Previous studies have demonstrated that prolonged treatment
with either systemic or topical GC alters epidermal structure
and function. For example, prolonged GC therapy is well known to
produce epidermal thinning, which, in turn, has been attributed to
both an inhibition of keratinocyte proliferation and an accelera-
tion in keratinocyte maturation (Laurence and Christophers,
1976; Delforno et al, 1978;Tammi, 1981; duVivier et al, 1982;Wood-
bury and Kligman, 1992). More recent studies have shown that
prolonged GC therapy also perturbs epidermal di¡erentiation, re-
sulting in a decrease in keratohyalin granule formation, as well as
a reduced expression of various protein markers of epidermal dif-
ferentiation (Sheu et al, 1991). Moreover, prolonged GC therapy
increases basal TEWL, indicating a defect in permeability barrier
function (Sheu et al, 1997). The decrease in barrier function asso-
ciated with prolonged GC therapy has been associated with a de-
crease in the thickness of the SC, a reduction in SC lipids, and a
decrease in the number of lamellar bodies in SG cells (Sheu et al,
1998). Yet, whereas it is clear that long-term GC treatment in-
duces marked changes in epidermal structure and function, these
studies provide few insights about the primary target of GC in
adult epidermis, and in such chronic models secondary changes
can obscure the primary e¡ects of GC treatment.
In this study, we demonstrate that even short-term treatment
with a potent GC, whether administered topically to humans
and either topically or systemically to adult mice, also adversely
impacts epidermal structure and function. Whereas such short-
term treatments produce no evident clinical changes (i.e., no ab-
normalities in basal TEWL), the kinetics of permeability barrier
recovery are delayed by 72 h of topical treatment with a potent
Figure 6. GC inhibit epidermal lipid synthesis. Hairless mice were topically treated twice per day with 0.05% clobetasol or vehicle alone for 3 d and
then skin samples were obtained for the determination of epidermal lipid synthesis either in the basal state (panel A) or 3 h following barrier disruption by
tape stripping (panel B). In separate experiments hairless mice were administered a daily intraperitoneal injection of 8 mg dexamethasone or vehicle alone and
skin samples were obtained in the basal state for the determination of epidermal lipid synthesis (panel C). Skin samples were incubated for 2 h with 14C
acetate and incorporation into the various lipid classes was determined as described in Materials and Methods. Dexamethasone decreased the lipid synthesis in
normal human keratinocytes from foreskin, grown in KGM with 0.02 mM Ca2þ to 90%^95% con£uence and subsequently changed to KGM with 1.2
mM Ca2þ for 3 d, and then changed to KGM with 1.2 mM Ca2þ without growth factors for 2 d. Finally, the normal human keratinocytes were changed
to KGM þ 1.2 mM Ca2þ without growth factor, with or without 0.1 mM dexamethasone. Results are expressed as mean7SEM and control values equal
100%. n¼ 4 for all groups except normal human keratinocytes where n¼ 5.
Figure 7. Topical GC reduce SC corneodesmosomes. Corneodesmo-
some (CD) density is profoundly reduced in clobetasol-treated SC (panel
A) versus vehicle-treated SC (panel B). The topical GC treatment reduced
the density of CD at the SG^SC interface. Panel A shows only a CD rem-
nant (black arrowhead) whereas prominent, large, intact CD could be seen in
vehicle-treated SC (panel B, black arrowhead). The densities of corneodesmo-
somes were also quanti¢ed in coded, randomized micrographs by an un-
biased observer (see text). A, B, RuO4 post¢xation.
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GC. The 3 d delay should not necessarily be misinterpreted as a
requirement for repeated or cumulative GC treatment, because
a single, supraphysiologic dose of GC rapidly inhibits epidermal
lipid synthesis in normal human keratinocytes. Instead, the 2þ d
delay in emergence of the barrier abnormality (1 d of topical
treatment did not adversely a¡ect barrier function) presumably
re£ects the time required for lipid-depleted granular cells to
replace competent SC cells in the lower SC. Moreover, whereas
basal barrier function is still normal at 72 h, both the density of
lamellar bodies and the amount of secreted lamellar body con-
tents at the SGSC interface are markedly reduced, re£ecting an
earlier e¡ect of GC in vivo as well. Thus, the e¡ects of short-term
GC can be compared to other types of short-term insults, such as
ultraviolet-B and irradiation (Haratake et al, 1997; Schmuth et al,
2001), where emergence of a barrier abnormality is delayed
because competent, preformed SC cells are replaced by a wave
of lipid-incompetent cells (Holleran et al, 1997).
Our results in adult human and murine skin contrast sharply
with the well-known positive e¡ects of exogenous GC on fetal
skin development (Hanley et al, 1996). Whereas we and others
have demonstrated negative e¡ects of GC on adult epidermis,
GC accelerate epidermal maturation and barrier formation late
in fetal development. The fact that GC positively regulate epider-
mal di¡erentiation in fetal skin but exert negative e¡ects in adult
skin may re£ect the orchestration of the same genes by di¡erent
sets of transcription factors or coactivators for example (Tucker-
mann et al, 1999). It should be noted that GC similarly regulate
lung development positively late in fetal development (Bolt et al,
2001), whereas GC generally exert negative e¡ects on a variety of
the same tissues in adults. Alternatively, some of the apparent dif-
ferences in response in fetal versus adult skin could also re£ect GC
doses.Whereas acceleration of epidermal maturation occurs with
physiologic to supraphysiologic concentrations of GC, we em-
ployed pharmacologic doses in these studies.
In addition to negative e¡ects on barrier homeostasis, topical
GC exert negative e¡ects on both the integrity and cohesion of
the SC. The decrease in SC integrity and adhesion is clinically
signi¢cant, because it would increase the susceptibility of the skin
to injury from relatively minor insults such as those that occur
with exposure to solvents, detergents, or mechanical forces.
Moreover, our study shows that this increased susceptibility ap-
pears early in therapy. Furthermore, the combination of an in-
creased susceptibility to barrier disruption with impairment in
barrier repair is also likely to have adverse consequences. For ex-
ample, short-term GC therapy, presumably in conjunction with
external trauma, can trigger exacerbations of psoriasis and other
diseases that are characterized by barrier abnormalities. The basis
for the GC-induced abnormality in SC integrity and cohesion
appears to be a reduction in the number of corneodesmosomes
in the SC. Studies are under way to determine whether the de-
crease in corneodesmosomes re£ects decreased formation of cor-
neodesmosomes or enhanced proteolysis. Interestingly, provision
of exogenous physiologic lipids not only restored permeability
barrier homeostasis but also improved SC integrity and cohesion,
suggesting that extracellular SC lipids in some way regulate SC
integrity and cohesion. Provision of lipids could restrict access of
proteases to corneodesmosomes. Alternatively, provision of free
fatty acids as part of the lipid mixture could further lower pH in
the SC interstices, thereby reducing the activities of SC chymo-
tryptic and tryptic enzymes, which display neutral pH optima
(Ekholm et al, 2000).
It should be noted that the ability of extracellular lipids to in-
£uence SC cohesion is amply demonstrated by the large number
of disorders of corni¢cation, both inherited and acquired, which
Figure 8. Treatment with topical lipids improves barrier homeostasis and SC integrity and cohesion in GC-treated animals. Hairless mice were
topically treated twice per day with 0.05% clobetasol or vehicle alone for 3 d. Immediately after each clobetasol treatment, animals were topically treated
with either a lipid mixture containing fatty acids, cholesterol, and ceramides or vehicle alone. Three groups were studied: clobetasol/vehicle, clobetasol/lipid
mixture, vehicle/vehicle. Barrier recovery was determined at 3, 6, and 24 h after disruption of the barrier by tape stripping (A). SC integrity (B) and cohe-
sion (C) were determined as described in Materials and Methods. Integrity re£ects changes in TEWL, measured as ppm per cm2 per h. Data in panel D show
hairless mice topically treated twice per day with 0.05% clobetasol or vehicle for 3 d. Immediately after barrier disruption by tape stripping animals were
treated topically with either a lipid mixture containing fatty acids, cholesterol, and ceramides or vehicle alone and barrier recovery was determined at 3, 6,
and 24 h.The pairwise comparison was performed after ANOVA testing (po0.05 in all cases). Panel D, control versus clobetasol, po0.01 for all strips; control
versus clobetasolþ lipids, po0.05 for two and three strips. Results are expressed as mean7SEM. n¼ 7 (A, B, C); n¼ 22 (D).
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are associated with primary abnormalities in lipid metabolism
(Williams, 1991). Furthermore, some SC lipids (e.g., free fatty
acids and cholesterol sulfate) are themselves protease inhibitors
(Sato et al, 1998).Whether the bene¢cial e¡ects of exogenous li-
pids on SC integrity re£ect an altered lipid composition or more
indirect e¡ects on SC protease activities remains to be deter-
mined.
It is likely that the decrease in SC lipids (Sheu et al, 1998) and
the increase in basal TEWL (Sheu et al, 1997) observed with
chronic GC administration are linked by the ability of GC to in-
hibit epidermal lipid synthesis in adult epidermis. Epidermal li-
pid synthesis is essential for the formation of lamellar bodies and
the extracellular lamellar membranes in the SC that mediate the
permeability barrier (Feingold et al, 1990; Holleran et al, 1991;
Mao-Qiang et al, 1993; Elias and Feingold, 1999). Here, we de-
monstrated that both topical and systemic GC inhibit the synth-
esis of the three key SC lipids, cholesterol, fatty acids, and
ceramides, which are required for lamellar body formation. The
inhibition of lipid synthesis occurs not only in the basal state,
but was even more profound following barrier disruption. Con-
comitant with this decrease in epidermal lipid synthesis we noted
(i) a decrease in lamellar bodies, (ii) a decrease in the quantity of
lamellar material delivered to the extracellular spaces of the SC,
and (iii) a decrease in extracellular lamellar bilayers in the SC.
Furthermore, in contrast to prior studies with hydrocortisone
(Ponec and Boonstra, 1987), a much less potent GC, we detected
a similar decrease in lipid synthesis in vitro in normal human ker-
atinocytes, evidence that the e¡ect of GC on epidermal function
occurs directly at the level of the epidermis. That these changes
are likely to account for the abnormality in permeability barrier
homeostasis is further demonstrated by the ability of topical phy-
siologic lipids to restore barrier homeostasis to normal. Thus, GC
inhibit epidermal lipid synthesis, resulting in a decrease in lipid
precursors available for the formation of lamellar bodies and the
downstream generation of lamellar bilayers, which mediate per-
meability barrier function.
The e¡ects of GC on lipid synthesis vary from tissue to tissue.
In the liver, GC stimulate fatty acid and cholesterol synthesis
(Kirk et al, 1976; Lin and Snodgrass, 1982; Berdanier, 1989; Giudet-
ti and Gnoni, 1998). This increase in synthesis contributes to the
increase in serum triglyceride and cholesterol levels that so often
accompanies systemic GC therapy (Stone, 1994), but GC inhibit
lipid synthesis in most extrahepatic tissues (Picard et al, 1980;
Stange et al, 1981; Berdanier, 1989; Loirdighi et al, 1992). There
are, however, exceptions to the generalization that GC stimulate
hepatic lipid synthesis but inhibit lipid synthesis in peripheral tis-
sues. For example, GC stimulate fatty acid synthesis in fetal lung
thereby providing lipid precursors for the synthesis of surfactant
(Rooney, 1989; Gonzales et al, 1990).
In summary, this study has several clinical implications. First,
whereas topical and systemic GC are utilized for the treatment
of a variety of skin disorders and other diseases, their use is asso-
ciated with adverse e¡ects. In this paper, we demonstrate that
provision of exogenous physiologic lipids by topical application
might prevent two abnormalities that occur with short-term
GC therapy, i.e., impaired permeability barrier homeostasis and
decreased SC integrity and cohesion.Whether topical lipids will
prevent the structural and functional abnormalities in the epider-
mis that result in impaired barrier homeostasis with long-term
GC therapy remains to be determined.The second clinical impli-
cation relates to the occasional £are in clinical symptoms that oc-
curs when patients with disorders such as psoriasis or atopic
dermatitis are treated with GC. It is noteworthy that both psor-
iasis and atopic dermatitis are associated with defective barrier
function (Ghadially et al, 1996; Fartasch, 1997) and that perturba-
tions in the barrier are already known to initiate or exacerbate
these disorders. It is therefore possible that GC treatment induces
disease £ares in these disorders by further impairing permeability
barrier function, and that topical lipid replacement again might
ameliorate these £ares. A third clinical implication of our study
is that we and others have demonstrated previously that acute
psychologic stress impairs barrier homeostasis (Garg et al, 2001),
and that such £ares are due to an increase in endogenous GC
(Denda et al, 2000). Many cutaneous disorders are initiated or ex-
acerbated by psychologic stress and it is likely that alterations in
barrier homeostasis could contribute to this adverse association. If
alterations in epidermal lipid synthesis underlie the adverse e¡ects
of stress on the epidermis, it might also become possible to em-
ploy topical lipid therapy to reduce these adverse e¡ects. Thus,
this study demonstrates that GC treatment acutely inhibits epi-
dermal lipid synthesis, which subsequently leads to abnormalities
in permeability barrier homeostasis and SC integrity and cohe-
sion. Replenishment of epidermal lipids by topical therapy re-
versed these abnormalities and represents a potential therapeutic
modality to reduce the adverse e¡ects of GC therapy.
These studies were supported by NIH grants HR 19098, HD 29706, and PO
039448, and the Research Service, Department ofVeterans A¡airs.
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